Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer

Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer

Personalized medicine: Mutated tumors respond to therapy Mutations in the p53 tumor suppressor gene could offer a predictive biomarker of response to certain drugs in triple-negative breast cancer. Jill Bargonetti from Hunter College in New York, USA, and colleagues showed that mutant p53, which is...

Full description

Bibliographic Details
Main Authors: Wei-Gang Qiu, Alla Polotskaia, Gu Xiao, Lia Di, Yuhan Zhao, Wenwei Hu, John Philip, Ronald C. Hendrickson, Jill Bargonetti
Format: Article
Language:English
Published: Nature Publishing Group 2017-01-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-016-0001-7

Internet

https://doi.org/10.1038/s41523-016-0001-7

Similar Items